Dr. Scher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Irving St Nw
Medical Service/Hematology
Washington, DC 20422Phone+1 202-745-8134
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1976 - 1977
NYU Grossman School of MedicineResidency, Internal Medicine, 1971 - 1976
Perelman School of Medicine at the University of PennsylvaniaClass of 1971
Certifications & Licensure
WV State Medical License 1978 - 2025
NY State Medical License 1972 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 41 citationsU.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic AcidMartin H. Cohen, Ramzi Dagher, Donna Griebel, Amna Ibrahim, Alison Martin
The Oncologist. 2002-10-01 - 46 citationsFDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J. Howie, Nancy S. Scher, Laleh Amiri-Kordestani, Lijun Zhang, Bellinda L. King-Kallimanis
Clinical Cancer Research. 2019-05-15 - 84 citationsFirst FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-positive Metastatic Breast CancerGideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang
Clinical Cancer Research. 2013-09-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
